Osmotica Pharmaceuticals (Nasdaq: OSMT) will present at the 2020 Jefferies Virtual Healthcare Conference on June 3, 2020, at 2:30 p.m. Eastern Time. The presentation will be led by Brian Markison, CEO, and Andrew Einhorn, CFO. It will be available via a live webcast, which can be accessed at this link and archived for 30 days on the Company's website under the “Investor & News” section.
Osmotica focuses on developing and commercializing specialty products for underserved patient populations.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and CFO Andrew Einhorn will present at the RBC Capital Markets Global Healthcare Virtual Conference. The event is scheduled for May 19, 2020, at 9:10 a.m. Eastern Time. Interested individuals can access the live webcast and archived presentation through Osmotica's website under the Investor & News section. Osmotica focuses on developing specialty products targeting underserved patient populations and operates in the United States, Argentina, and Hungary.
Osmotica Pharmaceuticals reported total revenue of $48.6 million for Q1 2020, down from $57.1 million in Q1 2019. The net loss improved to $3.1 million compared to $6.7 million a year ago. Adjusted EBITDA was $11.1 million, a decrease from $16.6 million in the previous year. Net sales of methylphenidate ER dropped 60% due to competition, and venlafaxine ER tablets saw a 35% decline in sales. The company is focused on launching RVL-1201 and filing an amended NDA for arbaclofen ER. Cash reserves stood at $125.8 million.
Osmotica Pharmaceuticals (Nasdaq: OSMT) will release its first quarter financial results for 2020 on May 12, 2020, after U.S. markets close. The executive team, including CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn, will host a conference call at 4:30 p.m. ET, accessible via toll-free lines and a webcast. The company focuses on developing and commercializing specialty products for underserved patient populations, with operations in the U.S., Argentina, and Hungary.